ArticleToxicology and applied pharmacology2019
The use of evidence from high-throughput screening and transcriptomic data in human health risk assessments.
Article in Toxicology and applied pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Analytical choices drive toxicogenomic potency estimates: a systematic evaluation of transcriptomic points of departure.Toxicological sciences : an official journal of the Society of Toxicology · 2026Article
- Predicting gene essentiality and drug response from preclinical perturbation screens with layered ensemble of autoencoders and predictors.Scientific reports · 2026Article
- Consensus findings of an International Workshops on Genotoxicity Testing workshop on using transcriptomic biomarkers to predict genotoxicity.Environmental and molecular mutagenesis · 2025Review
- Transcriptomic point of departure determination: a comparison of distribution-based and gene set-based approaches.Frontiers in genetics · 2024Article
- From vision toward best practices: EvaluatingFrontiers in toxicology · 2023Article
- A microRNA or messenger RNA point of departure estimates an apical endpoint point of departure in a rat developmental toxicity model.Birth defects research · 2022Article
- Challenges in Bone Tissue Regeneration: Stem Cell Therapy, Biofunctionality and Antimicrobial Properties of Novel Materials and Its Evolution.International journal of molecular sciences · 2020Review
- Gene Expression Thresholds Derived From Short-term Exposures Identify Rat Liver Tumorigens.Toxicological sciences : an official journal of the Society of Toxicology · 2020Article
- A Rat Liver Transcriptomic Point of Departure Predicts a Prospective Liver or Non-liver Apical Point of Departure.Toxicological sciences : an official journal of the Society of Toxicology · 2020Article
- Modernization of chemical risk assessment to make use of novel toxicological data.Toxicology and applied pharmacology · 2020Article
- The sensitivity of transcriptomics BMD modeling to the methods used for microarray data normalization.PloS one · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
High throughput screening (HTS) and functional genomics (toxicogenomics) have opened new avenues in toxicity testing. Their advantages include the potential for developing short-term in vivo bioassays and in vitro assays in order to keep pace with the growing backlog of chemicals that need to be evaluated for potential human health risk. In addition, these approaches have the potential to address some of the difficulties that arise with interpreting traditional rodent bioassays, such as the relevance of apical outcomes induced by chemical exposure in animals to humans. The wealth of information associated with the HTS and toxicogenomic data can inform human health risk assessment primarily through (i) insight into potential mechanism of action, (ii) prediction of adverse outcomes of chemical exposures, and (iii) dose-response assessment for derivation of toxicity values. In this article we outline current and expected future progress in these three directions and argue for increased role of HTS and toxicogenomic data in chemical risk assessment. We conclude that these approaches can help fulfill the NRC vision for toxicity testing in the 21st century and we discuss specific examples of chemicals whose health assessments can potentially benefit from available HTS or toxicogenomic data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.